Available EU DMF/CEP
EU DMF
CEP
API Status
Commercial
Pipeline
Therapeutic Category
Alimentary tract & metabolism
Anti-infectives for systemic use
Antipyretic, analgesic and anti-inflammatory
Antineoplastic & immunomodulating agents
Blood & blood forming organs
Cardiovascular system
Genito-urinary system & sex hormones
Injectable forms
Musculo-skeletal system
Nervous system
Opthalmological preparations
Respiratory system
Available US DMF
US DMF
Available Japanese/Chinese DMF
Japanese DMF
Chinese DMF
Korean DMF
Sort By
Alphabetical
Therapeutic Category
a
Acenocoumarol

Therapeutic Area

Cardiovascular system

Polymorphic form

CAS No.

152-72-7

Acetazolamide

Therapeutic Area

Cardiovascular system

Polymorphic form

Form II

CAS No.

59-66-5

Alendronate sodium

Therapeutic Area

Musculo-skeletal system

Polymorphic form

Trihydrate

CAS No.

121268-17-5

Aniracetam

Therapeutic Area

Nervous system

Polymorphic form

Monoclinic form

CAS No.

72432-10-1

Apixaban

Therapeutic Area

Blood & blood forming organs

Polymorphic form

Crystalline form N-1

CAS No.

503612-47-3

Apremilast

Therapeutic Area

Musculo-skeletal system

Polymorphic form

Form B, Form N

CAS No.

608141-41-9

Aripiprazole

Therapeutic Area

Nervous system

Polymorphic form

Type I

CAS No.

129722-12-9

Aripiprazole monohydrate (non-sterile)

Therapeutic Area

Nervous system

Polymorphic form

Monohydrate

CAS No.

851220-85-4

Avanafil

Therapeutic Area

Genito-urinary system & sex hormones

Polymorphic form

Crystalline, none

CAS No.

330784-47-9

b
Baclofen

Therapeutic Area

Musculo-skeletal system

Polymorphic form

Form B

CAS No.

1134-47-0

Baricitinib

Therapeutic Area

Antineoplastic & immunomodulating agents

Polymorphic form

Form I

CAS No.

1187594-09-7

Bazedoxifene acetate

Therapeutic Area

Alimentary tract & metabolism

Polymorphic form

Form A

CAS No.

198481-32-2

Brexpiprazole

Therapeutic Area

Nervous system

Polymorphic form

Polymorphic form I

CAS No.

913611-97-9

c
Carbamazepine

Therapeutic Area

Nervous system

Polymorphic form

Form III

CAS No.

298-46-4

Carvedilol

Therapeutic Area

Cardiovascular system

Polymorphic form

Form II

CAS No.

72956-09-3

Carvedilol phosphate hemihydrate

Therapeutic Area

Cardiovascular system

Polymorphic form

Form I

CAS No.

610309-89-2

Chlorpromazine hydrochloride

Therapeutic Area

Nervous system

Polymorphic form

Crystalline anhydrous form II

CAS No.

69-09-0

Clopamide

Therapeutic Area

Cardiovascular system

Polymorphic form

CAS No.

636-54-4

Cyclobenzaprine hydrochloride

Therapeutic Area

Musculo-skeletal system

Polymorphic form

Crystalline, none

CAS No.

6202-23-9

d
Dabigatran etexilate mesylate

Therapeutic Area

Blood & blood forming organs

Polymorphic form

Form I

CAS No.

872728-81-9

Dapagliflozin

Therapeutic Area

Alimentary tract & metabolism

Polymorphic form

Amorphous

CAS No.

461432-26-8

Dapagliflozin Propanediol Monohydrate

Therapeutic Area

Alimentary tract & metabolism

Polymorphic form

Crystalline SC-3

CAS No.

960404-48-2

e
Empagliflozin

Therapeutic Area

Alimentary tract & metabolism

Polymorphic form

Crystalline anhydrous

CAS No.

864070-44-0

Etodolac

Therapeutic Area

Musculo-skeletal system

Polymorphic form

Crystalline racemate, none

CAS No.

41340-25-4

h
Hydrochlorothiazide

Therapeutic Area

Cardiovascular system

Polymorphic form

Form I

CAS No.

58-93-5

i
Ibandronate sodium

Therapeutic Area

Musculo-skeletal system

Polymorphic form

Monohydrate

CAS No.

138926-19-9

l
Lamotrigine

Therapeutic Area

Nervous system

Polymorphic form

Anhydrous monoclinic

CAS No.

84057-84-1

Linaclotide

Therapeutic Area

Alimentary tract & metabolism

Polymorphic form

Amorphous

CAS No.

851199-59-2

Linaclotide

Therapeutic Area

Alimentary track & metabolism

Polymorphic form

Amorphous form

CAS No.

851199-59-2

Linagliptin

Therapeutic Area

Alimentary tract & metabolism

Polymorphic form

Mix of form A & B

CAS No.

668270-12-0

m
Metronidazole

Therapeutic Area

Anti-infectives for systemic use

Polymorphic form

Monoclinic crystal system with space group P21/c

CAS No.

443-48-1

n
Nefopam hydrochloride

Therapeutic Area

Nervous system

Polymorphic form

CAS No.

23327-57-3

o
Opipramol dihydrochloride

Therapeutic Area

Nervous system

Polymorphic form

Amorphous

CAS No.

909-39-7

Oxcarbazepine

Therapeutic Area

Nervous system

Polymorphic form

Forma A

CAS No.

28721-07-5

p
Pentoxifylline

Therapeutic Area

Cardiovascular system

Polymorphic form

Form I

CAS No.

1677687

Phenyl salicylate

Therapeutic Area

Antipyretic, analgesic and anti-inflammatory

Polymorphic form

Crystalline orthorhombic form

CAS No.

118-55-8

Pimavanserin tartrate

Therapeutic Area

Nervous system

Polymorphic form

Crystalline anhydrous form C

CAS No.

706782-28-7 (tartrate)

Piracetam

Therapeutic Area

Nervous system

Polymorphic form

Form II

CAS No.

7491-74-9

Prasugrel hydrochloride

Therapeutic Area

Cardiovascular system

Polymorphic form

Form B2

CAS No.

389574-19-0

Prasugrel maleate

Therapeutic Area

Cardiovascular system

Polymorphic form

Form 1

CAS No.

1373350-60-7

r
R-Baclofen

Therapeutic Area

Musculo-skeletal system

Polymorphic form

Form B

CAS No.

69308-37-8

R-baclofen hydrochloride

Therapeutic Area

Musculo-skeletal system

Polymorphic form

Crystalline HCl form

CAS No.

63701-55-3

Repaglinide

Therapeutic Area

Alimentary tract & metabolism

Polymorphic form

Form I

CAS No.

135062-02-1

Risedronate sodium

Therapeutic Area

Musculo-skeletal system

Polymorphic form

Form A

CAS No.

115436-72-1

Rivaroxaban

Therapeutic Area

Blood & blood forming organs

Polymorphic form

Modification I

CAS No.

366789-02-8

s
Sacubitril/Valsartan Complex

Therapeutic Area

Cardiovascular system

Polymorphic form

Crystalline

CAS No.

936623-90-4

Safinamide methanesulfonate

Therapeutic Area

Nervous system

Polymorphic form

Crystalline anhydrous modification A1

CAS No.

202825-46-5

Salicylamide

Therapeutic Area

Antipyretic, analgesic and anti-inflammatory

Polymorphic form

Monoclinic form (space group I2/a)

CAS No.

65-45-2

Saxagliptin hydrochloride

Therapeutic Area

Alimentary tract & metabolism

Polymorphic form

H2-1 (HCl*2H2O)

CAS No.

709031-78-7

Saxagliptin monohydrate base

Therapeutic Area

Alimentary tract & metabolism

Polymorphic form

Orthorhombic Form H-1

CAS No.

361442-04-8

Sildenafil base

Therapeutic Area

Genito-urinary system & sex hormones

Polymorphic form

CAS No.

139755-83-2

Sildenafil citrate

Therapeutic Area

Genito-urinary system & sex hormones

Polymorphic form

Anhydrous Form

CAS No.

171599-83-0

Sodium salicylate

Therapeutic Area

Antipyretic, analgesic and anti-inflammatory

Polymorphic form

Monoclinic form (space group P21/m)

CAS No.

54-21-7

Solifenacin

Therapeutic Area

Genito-urinary system & sex hormones

Polymorphic form

Form I

CAS No.

242478-37-1

t
Tadalafil

Therapeutic Area

Genito-urinary system & sex hormones

Polymorphic form

Form A (form I)

CAS No.

171596-29-5

Ticagrelor

Therapeutic Area

Blood & blood forming organs

Polymorphic form

Form II

CAS No.

274693-27-5

Tolterodine tartrate

Therapeutic Area

Genito-urinary system & sex hormones

Polymorphic form

Form 1

CAS No.

124937-52-6

Topiramate

Therapeutic Area

Nervous system

Polymorphic form

Orthorhombic structure

CAS No.

97240-79-4

v
Vardenafil hydrochloride

Therapeutic Area

Genito-urinary system & sex hormones

Polymorphic form

Trihydrate form

CAS No.

330808-88-3

x
Xylometazoline hydrochloride

Therapeutic Area

Respiratory system

Polymorphic form

CAS No.

1218-35-5

z
Zoledronic acid

Therapeutic Area

Musculo-skeletal system

Polymorphic form

Monohydrate

CAS No.

165800-06-6

DISCLAIMER
The above list is presented solely for informational purposes and does not constitute an offer in any sense. Products under patent (SPC) protection in Poland and/or other countries are not offered until expiration of the corresponding IP right.

Products protected by valid patents are not offered for commercial sale in countries where the sale of such products constitutes patent infringement but are offered solely for uses reasonably related to the development and submission of information under a law regulating the manufacture, use or sale of drugs. It is within the buyer’s responsibility and liability to check the patent situation of the product in the imported market(s).

OK